Current News

Contact | Print version | PDF version | Send article | RSS feed

Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market

28 Nov 2008 - The European autoimmune disease diagnostics market has demonstrated sustained growth due to advances in detection technology and automation. Active consolidation is occurring in the market, promoting technology and product integration. However, the lack of clarity with regard to reimbursement policies for autoimmune diagnostic tests persists, posing a challenge to market expansion.
 
New analysis from Frost & Sullivan, European Autoimmune Disease Diagnostics Market, finds that the market earned revenues of $513.5 million in 2008 and estimates this to reach $722.0 million in 2015.
 
"The development of novel biomarker panels has accelerated the diagnosis of many autoimmune complications,” notes Frost & Sullivan Research Analyst Suraj Ramanathan. "Exhaustive R&D by many universities and research organisations has yielded promising results in the use of multiple biomarkers for autoimmune disease diagnosis.”
 
The ability to screen a patient with multiple biomarkers associated with several autoimmune diseases has been shown to improve the accuracy of the diagnosis and has had a significant positive influence on the autoimmune disease diagnostics market. Such novel biomarker panels will continue to offer an added advantage to physicians in the diagnosis of these complications.
 
Despite the advances in detection technology, the generalised lack of awareness among the public with regard to autoimmune diseases presents a challenge to market growth.
 
"Such low levels of awareness may derive from the rarity of many autoimmune complications among the general population,” explains Ramanathan. "Many patients in Europe, unable to find a proper treatment for their condition, are consequently switching to traditional methods such as oriental medicine.”
 
The need is, therefore, to boost patient awareness. This can be achieved through extensive workshops and disease awareness programmes.
 
"In conjunction with medical research organisations and hospitals, manufacturers should establish awareness programmes and interactive workshops for the public,” advises Ramanathan. "These could highlight the prevalence of autoimmune diseases, while encouraging physicians to interact with the public on the symptoms, etiology and progression of autoimmune diseases.”
 
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European autoimmune disease diagnostics market, then send an e-mail to Patrick Cairns, using the 'Contact' button below.